Innovative Therapeutics Indalo Therapeutics focuses on developing integrin antagonists for serious fibrotic diseases such as NASH and IPF, presenting opportunities to partner in advanced antifibrotic treatments and related diagnostic tools.

Early-Stage Pipeline With a lead candidate, IDL-2965, in Phase 1 trials, there is potential for collaborations, licensing, or funding to accelerate development or expand the pipeline into other fibrotic indications.

Strong Scientific Legacy Founded on decades of integrin research and a proven track record with FDA approvals, the company offers a compelling partnership opportunity with innovative biotech and pharma firms seeking cutting-edge targeted therapies.

Funding and Growth With $9 million in funding and a close-knit team, there is room for strategic investments, joint ventures, or service collaborations to support clinical development and commercialization efforts.

Market Focus Targeting fibrotic diseases affecting vital organs, Indalo provides a potential entry point for companies interested in expanding their portfolio into fibrotic and inflammatory therapies, especially in early clinical stages.